<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">34375</article-id><article-id pub-id-type="doi">10.7554/eLife.34375</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Preserving neuromuscular synapses in ALS by stimulating MuSK with a therapeutic agonist antibody</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-103632"><name><surname>Cantor</surname><given-names>Sarah</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103633"><name><surname>Zhang</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103634"><name><surname>Delestrée</surname><given-names>Nicolas</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-47667"><name><surname>Remédio</surname><given-names>Leonor</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1509-0024</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103635"><name><surname>Mentis</surname><given-names>George Z</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-17291"><name><surname>Burden</surname><given-names>Steven J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3550-6891</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution content-type="dept">Skirball Institute of Biomolecular Medicine</institution>, <institution>New York University School of Medicine</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Center for Motor Neuron Biology and Disease</institution>, <institution>Columbia University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-103437"><name><surname>Glass</surname><given-names>Jonathan</given-names></name><role>Reviewing editor</role><aff><institution>Emory University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>steve.burden@med.nyu.edu</email> (SB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>02</month><year>2018</year></pub-date><volume>7</volume><elocation-id>e34375</elocation-id><history><date date-type="received"><day>14</day><month>12</month><year>2017</year></date><date date-type="accepted"><day>02</day><month>02</month><year>2018</year></date></history><permissions><copyright-statement>© 2018, Cantor et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Cantor et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-34375-v3.pdf"/><abstract><p>In amyotrophic lateral sclerosis (ALS) and animal models of ALS, including <italic>SOD1-G93A</italic> mice, disassembly of the neuromuscular synapse precedes motor neuron loss and is sufficient to cause a decline in motor function that culminates in lethal respiratory paralysis. We treated <italic>SOD1-G93A</italic> mice with an agonist antibody to MuSK, a receptor tyrosine kinase essential for maintaining neuromuscular synapses, to determine whether increasing muscle retrograde signaling would slow nerve terminal detachment from muscle. The agonist antibody, delivered after disease onset, slowed muscle denervation, promoting motor neuron survival, improving motor system output, and extending the lifespan of <italic>SOD1-G93A </italic>mice. These findings suggest a novel therapeutic strategy for ALS, using an antibody format with clinical precedence, which targets a pathway essential for maintaining attachment of nerve terminals to muscle.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>ALS Association</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Burden</surname><given-names>Steven J</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>R37 NS36193</award-id><principal-award-recipient><name><surname>Burden</surname><given-names>Steven J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>RO1 NS078375</award-id><principal-award-recipient><name><surname>Mentis</surname><given-names>George Z</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000065</institution-id><institution>National Institute of Neurological Disorders and Stroke</institution></institution-wrap></funding-source><award-id>T32 NS86750</award-id><principal-award-recipient><name><surname>Cantor</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Steven J Burden, holds a patent (#9,329,182) for 'Method of treating motor neuron disease with an antibody that agonizes MuSK'.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All procedures were approved and mice were maintained according to Institutional Animal Use and Care Committee (IACUC protocol number 160425) guidelines at NYU Medical School.</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-34375-supp-v3.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>